Henry Schein, Inc. (HSIC)
| Market Cap | 8.28B +2.1% |
| Revenue (ttm) | 13.38B +5.6% |
| Net Income | 395.00M -2.9% |
| EPS | 3.30 +3.0% |
| Shares Out | 113.92M |
| PE Ratio | 22.00 |
| Forward PE | 13.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,347,905 |
| Open | 72.91 |
| Previous Close | 72.72 |
| Day's Range | 72.25 - 73.99 |
| 52-Week Range | 61.95 - 89.29 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 87.21 (+19.98%) |
| Earnings Date | May 5, 2026 |
About HSIC
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, di... [Read more]
Financial Performance
In 2025, Henry Schein's revenue was $13.18 billion, an increase of 4.03% compared to the previous year's $12.67 billion. Earnings were $398.00 million, an increase of 2.05%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for HSIC stock is "Buy." The 12-month stock price target is $87.21, which is an increase of 19.98% from the latest price.
News
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking rep...
Henry Schein Transcript: Bank of America Global Healthcare Conference 2026
Q1 saw strong growth in dental, technology, and distribution, with margin expansion and reaffirmed value creation targets. DSOs and home solutions are key growth drivers, while ongoing initiatives in AI, pricing, and operational efficiency support a positive outlook for 2026.
Henry Schein Proxy statement: Proxy filing
Henry Schein filed a proxy statement on May 12, 2026, providing details for shareholder voting and corporate governance matters.
Henry Schein price target lowered to $97 from $104 at Baird
Baird lowered the firm’s price target on Henry Schein (HSIC) to $97 from $104 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results…
Henry Schein price target lowered to $82 from $88 at Mizuho
Mizuho lowered the firm’s price target on Henry Schein (HSIC) to $82 from $88 and keeps a Neutral rating on the shares.
Henry Schein price target lowered to $85 from $87 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Henry Schein (HSIC) to $85 from $87 and keeps a Neutral rating on the shares.
Henry Schein Earnings Call Transcript: Q1 2026
Q1 2026 saw 6.3% sales growth, margin expansion, and strong U.S. Dental and Global Technology performance, offsetting medical softness. Guidance for 2026 remains unchanged, with high-margin businesses nearing 50% of operating income and value creation initiatives driving future growth.
Henry Schein Earnings release: Q1 2026
Henry Schein released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Henry Schein Slides: Q1 2026
Henry Schein has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Henry Schein Quarterly report: Q1 2026
Henry Schein has published its Q1 2026 quarterly earnings report on May 5, 2026.
Henry Schein reaffirms annual profit forecast, beats Q1 estimates on dental strength
Henry Schein on Tuesday reaffirmed its annual forecast after beating Wall Street expectations for first-quarter profit as the medical supplies distributor saw strong demand across its dental business...
Henry Schein Slides: Corporate presentation
Henry Schein has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Henry Schein reports Q1 non-GAAP EPS $1.32, consensus $1.22
Reports Q1 revenue $3.4B, consensus $3.34B. “I am pleased with our strong Q1 results that reflect continuing momentum from the second half of last year as we grow market share…
Henry Schein reaffirms FY26 non-GAAP EPS view $5.23-$5.37, consensus $5.32
Reaffirms FY26 total sales growth view 3%-5% over 2025; and Adjusted EBITDA to grow mid-single digits compared with 2025.
Henry Schein Reports First Quarter 2026 Financial Results
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial res...
Henry Schein to Participate in Upcoming Investor Conferences in May
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will presen...
Dentrix Ascend Introduces Next Generation Clinical Workflow Built with AWS
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the launch of its Next Generation Clinical Workflow, a voice-driven, AI-enabled advancem...
Dentrix Ascend Opens Its MCP Layer, Bringing AI Agents and a Custom Build Platform to Dental Practices
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced support for the Model Context Protocol (MCP), an open layer inside Dentrix Ascend that e...
Henry Schein price target raised to $64 from $61 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Henry Schein (HSIC) to $64 from $61 and keeps an Underweight rating on the shares. The firm’s U.S. dental…
Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will ...
5 Hidden Stocks Set to Beat the S&P 500 in 2026
Ari Sass, President and Portfolio Manager of M.D. Sass shares his value‑driven playbook for finding hidden market winners before the crowd.
Henry Schein initiated with a Neutral at BTIG
BTIG initiated coverage of Henry Schein (HSIC) with a Neutral rating and no price target The firm says Henry Schein is a dental market leader both in the U.S. and…
Henry Schein initiated with a Buy at Citi
Citi initiated coverage of Henry Schein (HSIC) with a Buy rating and $100 price target The firm launched the animal health and dental sectors with a “cautiously optimistic” view. Citi…
Amazon Stock Is Underrated — And These 4 Picks Are Too
The AI trade is moving beyond Big Tech — and Ari Sass has the hidden value stocks Wall Street hasn't caught up to yet.
Henry Schein price target lowered to $90 from $100 at Evercore ISI
Evercore ISI lowered the firm’s price target on Henry Schein (HSIC) to $90 from $100 and keeps an Outperform rating on the shares. The firm made several price target adjustments…